Axovant Sciences Ltd. (AXON) Reports Q3 Loss Per Share of 64c

Axovant Sciences Ltd. (NYSE: AXON) reported Q3 EPS of ($0.64), $0.49 worse than the analyst estimate of ($0.15).

Axovant Sciences also today announced further details of three new clinical trials to address cognitive, behavioral and functional aspects of Lewy body dementia, a disease affecting approximately 1.4 million people in the U.S. Two out of the three studies were recently initiated and the third is expected to start later this quarter

For earnings history and earnings-related data on Axovant Sciences Ltd. (AXON) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• CAE, Inc. (CAE) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY27 EPS Guidance
• Logistic Properties of the Americas (LPA) Reports Q2 results